Regulation of NKG2D Expression and Signaling by Endocytosis

Trends in Immunology

Volumn 37, Issue 11, 2016, Pages 790-802

  Molfetta, Rosa ^a   Quatrini, Linda ^a,d   Zitti, Beatrice ^a   Capuano, Cristina ^b   Galandrini, Ricciarda ^b   Santoni, Angela ^a,c   Paolini, Rossella ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c IRCCS NEUROMED   (Italy)

^d CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; NATURAL KILLER CELL RECEPTOR NKG2D; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

CELL STRESS; ENDOCYTOSIS; HUMAN; INTERNALIZATION; INTRACELLULAR SIGNALING; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; PROTEIN STRUCTURE; REVIEW; ANIMAL; CAPPING PHENOMENON; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NATURAL KILLER CELL; NEOPLASM; PHYSIOLOGICAL STRESS; SIGNAL TRANSDUCTION; VIRUS INFECTION;

ANIMALS; ENDOCYTOSIS; GENE EXPRESSION REGULATION; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTOR AGGREGATION; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL; VIRUS DISEASES;

EID: 84992731485     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2016.08.015     Document Type: Review

References (77)

1. 1 Eagle, R.A., Trowsdale, J., Promiscuity and the single receptor: NKG2D. Nat. Rev. Immunol. 7 (2007), 737–744.
2. 2 Raulet, D.H., et al. Regulation of ligands for the NKG2D activating receptor. Annu. Rev. Immunol. 31 (2013), 413–441.
3. 3 Ullrich, E., et al. New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology, 2, 2013, e26097.
4. 4 Lanier, L.L., NKG2D receptor and its ligands in host defense. Cancer Immunol. Res. 3 (2015), 575–582.
5. 5 Cerwenka, A., et al. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 11521–11526.
6. 6 Diefenbach, A., et al. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413 (2001), 165–171.
7. 7 Smyth, M.J., et al. NKG2D function protects the host from tumor initiation. J. Exp. Med. 5 (2005), 583–588.
8. 8 Guerra, N., et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28 (2008), 571–580.
9. 9 Zafirova, B., et al. Altered NK cell development and enhanced NK cell-mediated resistance to mouse cytomegalovirus in NKG2D-deficient mice. Immunity 31 (2009), 270–282.
10. 10 Groh, V., et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419 (2002), 734–738.
11. 11 Ogasawara, K., et al. Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity 18 (2003), 41–51.
12. 12 Oppenheim, D.E., et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat. Immunol. 6 (2005), 928–937.
13. 13 Wiemann, K., et al. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J. Immunol. 175 (2005), 720–729.
14. 14 Coudert, J.D., et al. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood 106 (2005), 1711–1717.
15. 15 Waldhauer, I., Steinle, A., Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res. 66 (2006), 2520–2526.
16. 16 Molfetta, R., et al. c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells. Eur. J. Immunol. 44 (2014), 2761–2770.
17. 17 Quatrini, L., et al. Ubiquitin-dependent endocytosis of NKG2D–DAP10 receptor complexes activates signaling and functions in human NK cells. Sci. Signal., 8, 2015, ra108.
18. 18 Garrity, D., et al. The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 7641–7646.
19. 19 Bauer, S., et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285 (1999), 727–729.
20. 20 Wu, J., et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285 (1999), 730–732.
21. 21 Diefenbach, A., et al. Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat. Immunol. 3 (2002), 1142–1149.
22. 22 Gilfillan, S., et al. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat. Immunol. 3 (2002), 1150–1155.
23. 23 Billadeau, D.D., et al. NKG2D–DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat. Immunol. 4 (2003), 557–564.
24. 24 Horng, T., et al. NKG2D signaling is coupled to the interleukin 15 receptor signaling pathway. Nat. Immunol. 8 (2007), 1345–1352.
25. 25 Graham, D.B., et al. Vav1 controls DAP10-mediated natural cytotoxicity by regulating actin and microtubule dynamics. J. Immunol. 177 (2006), 2349–2355.
26. 26 Upshaw, J.L., et al. NKG2D-mediated signaling requires a DAP10-bound Grb2–Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. Nat. Immunol. 7 (2006), 524–532.
27. 27 Bryceson, Y.T., et al. Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. Blood 114 (2009), 2657–2666.
28. 28 Ohashi, M., et al. Post-translational modification of the NKG2D ligand RAET1G leads to cell surface expression of a glycosylphosphatidylinositol-linked isoform. J. Biol. Chem. 285 (2010), 16408–16415.
29. 29 Fernández-Messina, L., et al. The human NKG2D ligand ULBP2 can be expressed at the cell surface with or without a GPI anchor and both forms can activate NK cells. J. Cell Sci. 124 (2011), 321–327.
30. 30 Ashiru, O., et al. A GPI anchor explains the unique biological features of the common NKG2D-ligand allele MICA*008. Biochem. J. 454 (2013), 295–302.
31. 31 Groh, V., et al. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 12445–21250.
32. 32 Cosman, D., et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14 (2001), 123–133.
33. 33 Gasser, S., et al. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436 (2005), 1186–1190.
34. 34 Soriani, A., et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 113 (2009), 3503–3511.
35. 35 Cerboni, C., et al. The DNA damage response: a common pathway in the regulation of NKG2D and DNAM-1 kigand expression in normal, infected, and cancer cells. Front Immunol., 4, 2014, 508.
36. 36 Groh, V., et al. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc. Nat. Acad. Sci. U. S. A. 100 (2003), 9452–9457.
37. 37 Hüe, S., et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 21 (2004), 367–377.
38. 38 Meresse, B., et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 21 (2004), 357–366.
39. 39 Champsaur, M., Lanier, L.L., Effect of NKG2D ligand expression on host immune responses. Immunol. Rev. 235 (2010), 267–285.
40. 40 Bacon, L., et al. Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D. J. Immunol. 173 (2004), 1078–1084.
41. 41 Cao, W., et al. RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity. J. Biol. Chem. 282 (2007), 18922–18928.
42. 42 Salih, H.R., et al. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J. Immunol. 169 (2002), 4098–4102.
43. 43 Boutet, P., et al. Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J. Immunol. 182 (2009), 49–53.
44. 44 Zingoni, A., et al. Genotoxic stress induces senescence-associated ADAM10-dependent release of NKG2D MIC ligands in multiple myeloma cells. J. Immunol. 195 (2015), 736–748.
45. 45 Ashiru, O., et al. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res. 70 (2010), 481–489.
46. 46 Fernández-Messina, L., et al. Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands. J. Biol. Chem. 285 (2010), 8543–8551.
47. c cytokines and TGF-β1. Blood 118 (2011), 3019–3027.
48. 48 Doubrovina, E.S., et al. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J. Immunol. 171 (2003), 6891–6899.
49. 49 Clayton, A., et al. Human tumor-derived exosomes down-modulate NKG2D expression. J. Immunol. 180 (2008), 7249–7258.
50. 50 von Lilienfeld-Toal, M., et al. Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. Cancer Immunol. Immunother. 59 (2010), 829–839.
51. 51 Song, H., et al. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Cell. Immunol. 239 (2006), 22–30.
52. + T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells. Blood 113 (2009), 2955–2964.
53. 53 Deng, W., et al. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science 348 (2015), 136–139.
54. 54 Hedlund, M., et al. Human placenta expresses and secretes NKG2D ligands via exosomes that down-modulate the cognate receptor expression: evidence for immunosuppressive function. J. Immunol. 183 (2009), 340–351.
55. 55 Hanaoka, N., et al. NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease. J. Immunol. 185 (2010), 5732–5742.
56. 56 Coudert, J.D., et al. Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways. Blood 111 (2008), 3571–3578.
57. 57 Champsaur, M., et al. Intact NKG2D-independent function of NK cells chronically stimulated with the NKG2D ligand Rae-1. J. Immunol. 185 (2010), 157–165.
58. 58 Roda-Navarro, P., et al. Transfer of NKG2D and MICB at the cytotoxic NK cell immune synapse correlates with a reduction in NK cell cytotoxic function. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 11258–11263.
59. 59 Roda-Navarro, P., Reyburn, H.T., The traffic of the NKG2D/Dap10 receptor complex during natural killer (NK) cell activation. J. Biol. Chem. 284 (2009), 16463–16472.
60. 60 Galandrini, R., et al. Activation of lymphocyte cytolytic machinery: where are we?. Front. Immunol., 4, 2013, 390.
61. 61 Soriani, A., et al. Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1. J. Immunol. 193 (2014), 950–960.
62. 62 Cerboni, C., et al. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK-cell lysis. Blood 110 (2007), 606–615.
63. 63 Jung, H., et al. RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry. J. Exp. Med. 209 (2012), 2409–2422.
64. 64 Ward, J., et al. HIV-1 Vpr triggers natural killer cell-mediated lysis of infected cells through activation of the ATR-mediated DNA damage response. PLoS Pathog., 5, 2009, e1000613.
65. 65 Richard, J., et al. HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing. Blood 115 (2010), 1354–1363.
66. 66 Li, H., et al. Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2. Cell Cycle 10 (2011), 3346–3358.
67. 67 Textor, S., et al. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res. 71 (2011), 5998–6009.
68. 68 Irannejad, R., et al. Effects of endocytosis on receptor-mediated signaling. Curr. Opin. Cell Biol. 35 (2015), 137–143.
69. 69 Bergeron, J.J., et al. Spatial and temporal regulation of receptor tyrosine kinase activation and intracellular signal transduction. Annu. Rev. Biochem. 85 (2016), 573–597.
70. 70 Murphy, J.E., et al. Endosomes: a legitimate platform for the signaling train. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 17615–17622.
71. 71 Brubaker, S.W., et al. Innate immune pattern recognition: a cell biological perspective. Annu. Rev. Immunol. 33 (2015), 257–290.
72. 72 Kagan, J.C., et al. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat. Immunol. 9 (2008), 361–368.
73. 73 Kurgonaite, K., et al. Essential role of endocytosis for interleukin-4-receptor-mediated JAK/STAT signalling. J. Cell Sci. 128 (2015), 3781–3795.
74. 74 Rajagopalan, S., et al. Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol., 4, 2006, e9.
75. 75 Miah, S.M., et al. Ubiquitylation of an internalized killer cell Ig-like receptor by Triad3A disrupts sustained NF-κB signaling. J. Immunol. 186 (2011), 2959–2969.
76. 76 Chaturvedi, A., et al. Endocytosed BCRs sequentially regulate MAPK and Akt signaling pathways from intracellular compartments. Nat. Immunol. 12 (2011), 1119–1126.
77. 77 Willinger, T., et al. Dynamin 2-dependent endocytosis sustains T-cell receptor signaling and drives metabolic reprogramming in T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 4423–4428.